TENX$1.83+1.67%
Tenax Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$68.49M
Float & O/S:
Inst Own:
DilutionScan read 32 of TENAX THERAPEUTICS, INC.'s SEC filings and found 6 warrant series, 1 convertible and 3 shelf registrations on file for TENX. The latest dilution event on file is a registration statement on Apr 1, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
TENX
Phase 3 failure with cash runway
Snapshot
Tenax Therapeutics is a development-stage biotech with no revenue and a significant cash burn. The company reported a FY 2025 net loss of $52.6M but holds $118M in cash following warrant exercises, extending its operational runway into the second quarter of 2028.
What's Happening Right Now
- : Tenax announced that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary endpoint and a key secondary endpoint, though exploratory analyses showed some positive biomarker trends.
- : Tenax reported $118M in cash with a runway extending into Q2 2028, bolstered by warrant proceeds, while R&D expenses increased to $12.9M for the quarter.
- : Tenax signed a supply agreement with Orion Corporation to manufacture orally administered levosimendan, extending the regulatory approval deadline to 2035.
